Previous studies have reported both in vitro and in vivo that Sirt-1 expression is significantly decreased in response to Aβ25-35 treatment and in an AD model (Lattanzio et al., 2016[22]; Sun et al., 2019[41]). Here, SIRT1 is linked to Alzheimer disease.